Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

We should aim to achieve complete elimination of hepatitis C

I read the letters from Charles Gore (Clinical Pharmacist 2016;8:232) and Anja St. Clair Jones (Clinical Pharmacist 2016;8:264) on the therapies and new services for hepatitis C with interest. The points made are valid and important.

The key issues highlighted by Gore were related to the fact that there are real restrictions placed on accessing the newer therapies for this infection that have not been imposed in other disease areas, with other medicines, in other patients. Resources are limited; however, denying individuals timely access to National Institute for Health and Care Excellence-approved, evidence-based, cost-effective therapies is, indeed, exceptional.

St. Clair Jones points out the advances that have been made — the effective early access programme for the newer therapies, the setting up of functional operational delivery networks, the potential for accurate data collection, etc, — and although these are undoubtedly true, the direct rationing of access to the newer advances is equally true.

A rebuttal often heard is that those with severe disease, with impending likelihood of morbidity and mortality, can access treatment promptly, and those with milder disease can wait for treatment. This misses two important aspects. The first is that patients may progress more rapidly than expected or disengage with care, and therefore develop significant liver disease or illness while deemed to be suitable for ‘waiting’. The second is that hepatitis C is a transmissible infection, and while someone is denied treatment it is possible that further individuals may become infected. There is therefore a different paradigm from most other disease areas — treatment for the public good and for public health.

We have the potential tools and structures to aim for elimination of hepatitis C from our populations. What we need is political will, access to the medicines, and programmes to diagnose the undiagnosed and engage the disengaged. We could then make a huge difference to our and future generations. We require the pharmaceutical companies to be more realistic in their drug costings, and more flexible systems to allow payers to commission innovatively and effectively. We could achieve elimination. What other illnesses could we say this for? We should work at realising this potential.

Andrew Ustianowski

Chair of the British Viral Hepatitis Group and consultant in infectious diseases

North Manchester General Hospital

Citation: Clinical Pharmacist DOI: 10.1211/CP.2016.20201704

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Complete Guide to Medical Writing (The)

    Complete Guide to Medical Writing (The)

    Effectively communicate scientific and medical information with The Complete Guide to Medical Writing.

    £26.00Buy now
  • Popular Medicines

    Popular Medicines

    An illustrated history of some of the most popular branded medicines. Includes colourful historical adverts and details of the medicine's formula and intended purpose.

    £21.00Buy now
  • Clarke's Analysis of Drugs and Poisons

    Clarke's Analysis of Drugs and Poisons

    Clarke's Analysis of Drugs and Poisons is the definitive reference source of analytical data for drugs and poisons.

    £520.00Buy now
  • Basic Pharmacokinetics

    Basic Pharmacokinetics

    A clear and concise basic pharmacokinetics textbook. Shows how to apply the principles to achieve successful drug therapy.

    £52.00Buy now
  • Martindale: The Complete Drug Reference

    Martindale: The Complete Drug Reference

    Martindale: The Complete Drug Reference provides reliable, unbiased and evaluated information on drugs and medicines used throughout the world.

    £550.00Buy now
  • Pharmacy Registration Assessment Questions

    Pharmacy Registration Assessment Questions

    Pharmacy Registration Assessment Questions features over 400 closed book and calculation questions. With the registration exam having gone through a complete transformation in 2016, this volume has been developed around the new General Pharmaceutical Council (GPhC) guidelines.

    £32.00Buy now

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.